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1183-67 Alteration of L-Type Calcium Currents in Human 
Cardiopathy 
Florence Leclercq, Sthphanie Barrere-Lemarre, Christophe Piot, Jean-Marc Frapie, Joel 
Nargeot. Sylvain Richard, Human Genetic Institute. Montpellier, France, Amaud de 
Villeneuve Hospital, Montpellier, France 
Background. There are controversies concerning calcium currents changes associated 
with different stages of cardiopathy (compensated hypertrophy or heart failure). 
Methods. Human myocytes (n=160) were obtained from right atrial appendages during 
open-heart surgery in 40 patients (pts) with acute (groupA) or chronic (group B) cardiop- 
athy. Group A included pts with recent (less than one month) mitral regurgitation (MR) 
linked to chordal tendinee rupture (3 pts, n=13); group B included pts with chronic MR (6 
pts, n=21). aortic stenosis (5 pts, n=16), aortic regurgitation (6 pts, n=32), ischemic cardi- 
opathy (20 pts, n=78). Calcium current ICaL was recorded from freshly dissociated myo- 
cytes with the whole-cell patch-clamp technique. Cell capacitance (picofarad: pf), ICaL 
peak amplitude (picoampere: PA), and ICaL density (pA/pF) were measured. Left vsntric- 
ular (LV) dilatation and/or hypertrophy (echocardiography). LV ejection fraction (angio- 
graphic determination), NYHA functional class, age and therapy were taken into account. 
Results. In group A, ICaL peak amplitude was 490+/-60pA, ICaL density was 6.5 +/-0.8 
pA/pF, and cell capacitance was 76+/-15 pF. In comparison, group B was characterized 
by highly significant reduction of both ICaL peak and density (220+/-l 5 pA and 1.7 +I-2 
pA/pF; pcO.0001) and by a twofold increase of cell capacitance (142+/-55 pF; p<O.OOl). 
In group B. cell capacitance was markedly larger in advanced (LVEF<35%) ischemic car- 
diopathy (178+/-13 pF; p<O.Ol) whereas a dramatic decrease of peak current was asso- 
ciated with chronic MR (98+1-34 pA; p-zO.001). LVEF and NYHA class were not predictive 
of ICaL peak amplitude. Calcium channel antagonists and/or B-blockers therapy had no 
significant effect on current whereas age > 70 years and LV dilatation were significantly 
related to reduced ICaL density (pcO.01). 
Conclusion. There is a reduction of ICaL peak density associated with chronic cardiopa- 
thy in human. However, decrease in peak ICaL amplitude and/or increase in cell capaci- 
tance may have variable contribution in different diseases. Alteration of calcium currents 
in right atrial myocytes may reflect involvement of hemodynamic, neurohormonal or sys- 
temic factors. 
all (n=7) and from LV of 6 normal (NL) dogs. Using specific primers in reverse tren- 
SCriptSSS-pOlynWSSS chain reaction, BNP and ANP were identified on agarose-ethidium 
gel; corresponding fluorescent bands were quantified in densitometric units and normal- 
ized to glyceraldehyde-3 phosphate dehydrogenase (GAPDH), a housekeeping gene. 
Results: The results are shown in the table. Exoression of both BNP and ANP increased 
in untreated HF dogs compared to NL. Treatment with ER-MET reduced mRNA expres- 
sion of both BNP and ANP when cornoared to untreated HF doos. Conclusions: The 
findings Indicate that in dogs with HF, monotherapy with ER-MET reduces mRNA 
expression of both BNP and ANP. These findings are consistent with the observed 
reduction in mortality and morbidity in patients with HF. 
NL HF-Untreated 
BNP/GAPDH 0.54 + 0.02 1.60+0.10’ 0.64 + 0.07’* 
ANP/GAPDH 0.48 -+ 0.05 1.32+0.03’ 0.82 f. 0.03”’ 
‘=P<O.O5 vs. NL; “=P<O.O5 vs. HF-Untreated 
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1184-70 Carvedilol Treatment Is as Well Tolerated as 
Angiotensin Converting Enzyme Inhibition in Patients 
With Chronic Heart Failure: Results of the CARMEN 
(Carvedilol ACE Inhibitor Remodeling Mild CHF 
EvaluatioN) Study 
1183-68 Pur fl, a Single Stranded DNA Binding Protein 
Represses SRF Mediated Muscle Gene Expression: 
Implications in Impaired Cardiac Muscle Gene 
Expression During Heart Failure 
Madhu Gupta, Vithida Sueblinvong, Mahesh P. Gupta, The Heart Institute for Children, 
Hope Childrens Hospital, Oak Lawn, IL, The University of Chicago, Chicago, IL 
Background: Pur proteins play a role in cell growth and differentiation by modulating cell 
cycle progression, replication and transcription of certain genes including smooth muscle 
actin. We have previously identified a strong negative regulatory element (PNR) at +66 to 
+108 bp region of cardiac aMHC gene. PNR collaborated with positive regulatory factors 
a interacting within the -200 bp promoter region of this gene, encompassing SREs 
(serum response elements). We subsequently cloned one of the transcription factors 
binding to PNR as Purp. This study examined the role of PurP in SRF mediated activation 
of a-MHC gene promoter. 
Methods: Transient transfection assays in primary cultures of cardiomyocytes analyzed 
the effect of SRF or Purp, alone or in combination on a-MHC promoter activity using 
luciferase as reporter. Gel -shift assay analyzed DNA-protein interaction. 
Results: Transfection of SRF cDNA activateda-MHC promoter/luciferase activity by 3 to 
5 fold. Inclusion of Puti exoression vector reduced SRF mediated activation bv 1 to 2. 
fold. Purp alone caused 40% repression of basal activity of a-MHC gene promoter. Gel- 
shift assay usino cardiac and Sol8 nuclear extracts and SRE of a-MHC demonstrated 
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two DNA-nuclear protein complexes, upper complex (UC) and lower (LC) complex. 
Super shift assay using specific antibody against Purp established LC as Purp. The 
specificity of this interaction in cardiac nuclear extract was examined further by using 
SREs of various muscle genes and of c-fos gene. Muscle SREs produced UC and LC 
whereas c-fos SRE produced only UC. Purified GST- Pulp protein showed sequence 
specific interaction with three different SREs of muscle genes but none with c-fos SRE. 
Competitive binding was observed between in vitro synthesized SRF and GST- PurPfor 
muscle SRE. Western blot and Northern blot analysis showed 3-fold induction in PurP 
expression in rat hearts subjected to pressure load with 70% decrease in a-MHC mRNA 
was observed. 
Conclusion: Purbthrough its interaction with SRE represses SRF mediated activation of 
a-MHC gene expression. Increased level of this protein in pressure load hypertrophy 
suggest its involvement in reducing the mRNA level of a-MHC. 
1183-69 Chronic Monotherapy With Extended Release 
Metoprolol Succinate Attenuates mRNA Gene 
Expression of Brain and Atrial Natriuretic Peptides in 
Left Ventricular Myocardium of Dogs With Heart Failure 
Sharad Rastoai, Ramesh C. Gupta, Sudhish Mishra, Hideaki Morita, George Suzuki, 
Sidney Goldstein, Hani N. Sabbah. Henry Ford Health System, Detroit, Ml 
Background: Plasma levels of brain (BNP) and atrial (ANP) natriuretic peptides are 
increased in heart failure (HF) and are predictive of poor outcome. Therapy with 
extended release metoprolol succinate (ER-MET) was shown to reduce mortality and 
morbidity in patients with HF. We previously showed that monotherapy with ER-MET 
increases LV ejection fraction and attenuates LV remodeling in dogs with chronic HF. In 
the this study, we examined the effects of ER-MET, a selective p, -receptor antagonist, 
on mRNA gene expression of BNP and ANP in LV of dogs with microembolization- 
induced HF. Methods: Total RNA was isolated from LV tissue of 14 dogs with HF ran- 
domized to 3 months therapy with ER-MET (50 mg, once daily, n=7) or to no therapy at 
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HF + ER-MET 
Michel Komaida, Hugo Madeira, Kristian Thygssen. Marco Bobbio, Wybren Jaarsma, 
Guenther Riegger, Jordi Soler-Soler. Lars Ryden, Per Hildebrandt, Beatrix Lutiger, 
Willem Remme, on behalf of the CARMEN investigators, Pitie Salpetriers Hospital, Paris, 
France, STICARES Cardiovascular Research Foundation, Rhoon. The Netherlands 
Background: Although current treatment guidelines for chronic heart failure (CHF) rec- 
ommend ACE-I and eblockers, P-blockers are still grossly underused. Their historical 
contra-indication and the perception of a difficult up-titration might have added to the 
slow uptake of P-blockers despite their proven reduction of mortality and morbidity in 
CHF patients. The aims of the CARMEN study were to compare the effects on cardiac 
remodeling, safety and tolerability of the ACE-I Enalapril (E) against Calvedilol (C) a 
combined PI&a,- blocker. 
Methods: CARMEN is a parallel-group, 3.arm, double-dummy study conducted I” 13 
European countries. Patients were randomized to C&E, C or E treatment arms, uptitrated 
on C to 25mg (50mg in patients 2 85kg) bid target dose and/or E to 1Omg bid target 
dose, and continued for 18 months. In the C&E arm, C was uptitrated first. Effects on left 
ventricular (LV) remodeling were assessed by echocardiography at baseline, months 
6.12 and 18. Hospitalizations and deaths were adjudicated by a blinded endpoint com- 
mittee. 
Results: The safety population included 572 mild CHF patients (C&E = 191; C = 191; E 
= 190). Mean age was 62 years, with 81% male. 65% were treated with an ACE-I 
whereas only 6% received a bblocker prior to study start. LV end systolic volume index 
was reduced in both C&E and C groups, but not in E. Similar percentages of patients 
were withdrawn 31%, 30% and 30%. experienced serious adverse events (AE) 28%. 
29% and 34% and any AE 79% (497 AE), 77% (426 AE) and 75% (461 AE) in the C&E, 
C and E arm. respectively. The number of deaths was equal in all groups (N=14) with 6, 
9 and 10 cardiovascular deaths in the C&E, C and E arm, respectively. All-cause and 
cardiovascular hospitalizations occurred in 26%. 27% and 32% and in 8%, 10% and 15% 
of patients in the C&E, C and E arms, respectively. Notably, there was no difference in 
AE during uptitration. 
Conclusion: All three treatment arms showed a very similar safety profile. In contrast to 
common perception, there was no difference in tolerability between an ACE-I and C. This 
result is even more remarkable as the high prestudy use of ACE-I might have introduced 
a bias by selecting ACE-I tolerant patients, who were only switched from their former 
ACE-I to E. 
1184-71 Predictors of p-blocker Utilization in Managed Care 
Patients With Heart Failure 
Carla A. Sueta, David W. Brown, Jill McCardle, Alain Bertoni, David Gaff. Medical 
Review of North Carolina, Gary, NC, Wake Forest University, Winston-Salem, NC 
Background: Heart failure(HF) is an increaslng cause of mortality and morbidity. 
Despite clinical trials and evidence-based guidelines that recommend P-blockers in 
patients with systolic dysfunction, utilization is low. The North Carolina Achieving Cardiac 
Excellence Project is designed to increase the utilization of angiotensin converting 
enzyme inhibitor(ACE-I) and P-blocker therapies in managed care patients(pts) with sys- 
tolic HF. The purpose of this study is to determlne the predictors of Pblocker prescription 
at baseline. 
Methods: Data obtained from outpatient medical record abstraction were available for 
1501 pts treated for HF in 2000. Pts on dialysis or with contraindications to p-blockers 
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were excluded. For this study, pts were randomly assigned either to a model deriva- 
tion(n=750) or validation(n=751) group. Logistic regression was used to identify those 
patient characteristics that best predicted P-blocker utilization in the derivation group. 
Modal goodness-of-fit was assessed. and the model validated. 
Results: The mean age of the population was 67215 yrs, 55% were women, 25% were 
African American and 69% had coronary altery disease. Assessment of left ventricular 
funcbon(LVF) was documented in 90% of pts. ACE-I therapy was prescribed in 76% and 
P-blockers were prescribed in 50% overall and in 59% of pts with systolic HF. In the deri- 
vation model, characteristics associated with receiving P_blockers included documented 
LVF(p<O.Ol). systolic dysfunction(pcO.Ol), coronary artery disease(p<O.Ol), inSurance 
type(p<O.Ol), and hypertenslon(p=03). Trends were noted for younger age(pc0.01) and 
ACE-I therapy(p=O.Ol), In the final multivariate model, coronary artery disease, docu- 
mented LVF, hypertension, and insurance type were significant predictors of P-blocker 
therapy Area under the ROC curve for both the final model and the derwation sample 
was 0.67. 
Conclusions: Although not optimal, eblocker utilization in patients with HF is higher 
than previously reported. Important predictors of eblocker prescription I” this sample of 
managed care pts are documented LV function and coronary artery disease. Strategies 
to increase &blocker therapy should be developed. 
long-term reductions an LV volumes, in contrast to ongoing ACE-I alone. Despite a 
change in therapy, C patients did not experience more adverse events and a similar 
number of patients completed the study. Therefore, Carvedilol might be regarded as pos- 
sible alternative to ACE-I in mild CHF patients. 
1184-74 Effects of Intravenous Nesiritide on Coronary 
Vasomotor Regulation and Myocardial Oxygen 
Extraction 
Andrew D. Michaela Andrew Klein, Kanu Chatterjee, University of California, San 
Francisco, San Francisco, CA 
1184-72 Mortality and Morbidity in Men, Women, and 
Postmenopausal Women in Val-HeFT 
Silia K. Maiahalme, Lawrence Baruch, Nora Aknay, Liselotte GoedsCMeinen, Monika 
Hofmann. Nancy Feliciano, Tampere University Hospital, Tampere, Finland 
Background: The Influence of gender on treatment and suwival in congestive heart fall- 
ore (HF) is understudied. Here, post-hoc analyses of primary endpoints of mortality (M) 
and combined mortality/morbidity and secondary endpoint of non-fatal morbidity (NFM) 
examined differences in men. women and postmenopausal women (age _> 55years) in 
the Valsartan Hear? Failure Trial (Val-HeFT). Methods: 5010 HF patients (4007 men and 
1003 women) were randomized to either valsartan (V) or placebo (P) in addition to pre- 
scribed HF therapy. Outcomes in pooled populations (V+P) and treatment effects (V vs 
P) were evaluated using Cox regression analysis. 
Results: Regardless of subgrouping by age above or below 55, the pooled population of 
women had lower M than men (16.3% vs 20.4%, p=O.O02) but women. especially post- 
menopausal women (n=791) had higher NFM (subgroup: Z55years - 21.1% vs 17.4%, 
p=O.O35). However, women with coronary heart disease, regardless of age above or 
below 55, had similar M as men (20.5% vs 22.6%, ~~0.187) while the higher rate of NFM 
remained (24.5% vs 16.3%, p<O.OOl). Similar results were seen wth diabetes co-mor- 
bidity. The use of background therapy wth ACE inhibitors, digoxin, O-blockers and diuret- 
ICS was similar between women and men, and none of these therapies had an Impact on 
gender differences within the pooled population. Between-treatment analyses for V vs P 
within males, females and post-menopausal females demonstrated a favorable effect or 
trend on combined mortality/morbidity endpoint in all three subgroups. 
Background: Nesiritide (Natreco@ Scios Inc., Sunnyvale, CA) is a recombinant form of 
human B-type natriuretic peptide, that has been shown to be beneficial in patients with 
decompensated congestive heart failure. This study evaluated the effects of nesiritide on 
coronary blood flow (CBF) and myocardial oxygen extraction. 
Methods: Patients referred for cardiac catheterization were enrolled. Patients who had 
baseline SBP < 95 mm Hg, were on vasopressors. and had received nitroglycerin or cal- 
cium blockers within the previous 24 hours were excluded. After diagnostic catheteriza- 
tion and full heparinization, a O.OlCinch Doppler FloWire was positioned in the proximal 
portion of an unobstructed coronary artery to measure average peak velocity (APV). 
Right heart catheterization and simultaneous blood gas sampling from the coronary sinus 
and aorta were performed at baseline and after a 30.min IV infusion of nesiritide (2mcg/ 
kg bolus and 0.01mcgikglmin). Quantitative coronary angiography was performed at 
baseline, lBmin, and 30-min. CBF=(coronary altery area)(APV)(0.3). Coronary resis- 
tance=mean arterial pressure/CBF. 
Results: Ten patients were enrolled. The mean age was 56*12 years (range 43-60). 
Three were female. Mean left ventricular ejection fraction was 46+20% (range 20.70%). 
During nesiritide infusion, pulmonary capillary wedge pressure decreased 46% 
(p=O.O02). mean pulmonary artery pressure decreased 19% (p=O.O3). systemic vascular 
resistance decreased 6% (p&22), and mean arterial pressure decreased 11% 
(p=O.O07). There was no significant change in cardiac output. Coronary artery APV 
increased from 21+6 cm/s at baseltne to 24i7 cm/s at 5 min (p=O.Ol), returning to base- 
line at 15 and 30 minutes. Coronary artery diameter increased 15% at 15. and 30.min 
(p=O.O07). CBF increased 33% at 15 min (p=O.O3) and 32% at 30 min (p=O.O7). Coronary 
resistance decreased 29% at 15 min (p=O.O2) and 29% at 30 min (p=O.O4). Myocardial 
oxygen extraction decreased 5% at 30 min (p=O.13). 
Conclusion: Nesiritide exerts coronary vasodilator effects, in both the epicardial conduc- 
tance and resistance arteries. There is a trend toward decreased myocardial oxygen 
extraction during nesiritide infusion. 
1184-75 Effect of Nonsurgical Heart Failure Therapies on 
Functional Mitral Regurgitation: A Meta-Analysis 
Conclusions: In Val-HeFT. the female gender was associated with lower M but a higher 
rate of NFM, especially for postmenopausal women. Primary HF etiology of coronary 
heart disease or a history of diabetes dilutes the gender benefit for M independent of 
age. These findings suggest that serious attention should be paid to postmenopausal 
women and those with comorbidities. Future studies should continue to enroll more 
female patients. Gender differences in HF M and NFM must be seriously considered both 
I” clinical practice and in the design of future HF studies. 
Madhavi Kadivala Martin Fewerman. Jason M. Lazar, Winthrop-University Hospital, 
Mineola, NY 
Background: Functional mitral regurgitation (MR) is a common echocardiographic find- 
ing in patients with congestive heart failure (CHF) and its presence and magnitude are 
associated with an adverse prognosis. The objective of this systematic overview using 
meta-analysis was to assess effects of hearl failure therapies on functional MR. 
Methods: Studies ware retrieved using medline and ovid (key words: mitral regurgitation, 
heart failure treatment). All clinical trials published I” English from 1965 to the present 
date ware included. Eighteen previously published studies met the criterion for our analy- 
sis. In these studies Doppler echocardiography was used to assess the degree of MR 
before and at least 1 month after the initiation of ace inhibitors (ace-l), beta-blockers (bb) 
or pacing in patients with CHF. Standardized effect size of reduction in MR was calcu- 
lated using Cohen’s ‘d’ for each study. Random effects model was used for the meta- 
analysis. Pearson’s correlation analysis was performed to assess the relation between 
various echo parameters and MR. 
Results: Functional MR was assessed in a total of 594 patients in 18 trials (4 ace-l, 4 bb 
and 10 pacing). By unweighted analysis, ace-l reduced MR by 59i 20% With the major- 
ity of patients on background ace-l therapy. bb reduced MR by 55i 24%. Pacing reduced 
MR by 26+ 15%, when added to optimal medical therapy. In a random effects model, the 
effect size (d) of MR reduction by ace-l and bb was large, d = - 1.04+ 0.36 (95% Cl - 
1.75, -0.34) and -i.l& 0.36 (95% Cl -1.86;0.46) respectively. Pacing therapy had a 
moderate effect on reduction of MR ( d= -0.59+ 0.06 (95% Cl -0.76, -0.43)). Pearson’s 
correlation analysis of effect sizes showed a trend toward reduction in MR correlating 
with an improvemerit in LV ejection fraction (r= -0.38, p ~0.15) and decrease in LV end 
diastolic diameter (r= 0.46, p= 0.11). 
Conclusion: In petlents with CHF and functional MR, ace-l and bb reduce MR to a large 
extent. Pacmg including cardiac resynchronization therapy reduced MR to a moderate 
extent. Further studies are required to understand the mechanism of these therapies on 
MR. 
1184-73 Replacement of Angiotensin Converting Enzyme 
Inhibition by Carvedilol Results in Long-Term Reversed 
Left Ventricular Remodeling in Mild Heart Failure and Is 
Well Tolerated: Results of the CARMEN (Carvedilol Ace- 
inhibitor Remodeling in Mild heart failure EvaluatioN) 
Study 
Willem J. Remme, Jordi Soler-Soler, Lars Ryden, Per Hildebrandt. Marco Bobbio, 
Wvbren Jaarsma, Michel Komaida, Armin Scherhaa. Guenther Rieaaer, on behalf of the 
&MEN investigators, Sticaras, Rotterdam, The Netherlands -_ 
Background: In chronic heart failure (CHF), the effect of Pblockade on mortality. mor- 
bidity and cardtac remodeling have always been evaluated in addition to ACE-I. It is 
unknown whether the combination is mandatory or whether in terms of remodeling ACE- 
I can successfully be replaced by eblockade. CARMEN compared the effect on remod- 
eling of the ACE-I Enalapr~l (E) against Carvedilol (C), a combined pl .@2 -blocker with 
additional al-receptor blockade and anti-oxidant properties. 
Methods: A parallel-group, 3.arm. double-dummy, multi-center study was conducted in 
13 European countries. Patients ware randomized to C &E. C and E treatment, uptitrated 
on C to 25mg BID target dose and/or E to 1Omg BID target dose, and continued for 16 
months. Earlier ACE-I and P-blocking treatment was stopped prior to randomization. In 
the C&E arm, C was uptitrated first. Effects of left ventricular (LV) remodeling were 
assessed by transthoracic echocardiography (biplane) at baseline. months 6, 12 and 16 
at a central core laboratory 
Results: 572 mild CHF patients, mean age 62 years, 61% males, were randomized. Of 
these, 65% (N=374) had been on ACE-I treatment prior to the study start, whereas only 
6% were on p-blockade. A subgroup analysis of the primary endpoint in former ACE-I 
users showed that LV end-systolic volume index was reduced at month 16 by 4.7 ml& 
(p=O.O06) I” the C group (n=l03) and by 6.0 ml/m2 (p=O.OOi) in the C&E group (n=ll4) 
from baseline. In contrast, in the E group (n=lOl) it increased by 0.6 ml/m2 (ns). The 
overall safety and tolerability profiles were comparable. In groups C&E, C and E adverse 
events occurred in 76%,75% and 74 %, respectively, whereas similar percentages of 
patients completed treatment (74%,70% and 72% respectively). 
Conclusion: Combination therapy (C&E) gave best results. However, replacement of 
ACE-I with C also resulted in significant reversal of cardiac remodeling with sustained, 
1184-76 Do Statins Provide Clinical Benefit in High-Risk 
Coronary Artery Disease Patients With Advanced Left 
Ventricular Dysfunction? 
Sandra P. Revna Benjamin D. Home, Robert R. Pearson, Tami L. Bair, Chloe A. Allen 
Maycock, Kismet D. Rasmussen, Jill Hall, Stephanie V. Moore, Jeffrey L. Anderson, 
Joseph B. Muhlestein, Dale G. Renlund, LDS Hospital, Salt Lake City, UT, University of 
Utah, Salt Lake City, UT 
Background: HMG-CoA reductase inhibitors (statins) are one of the most potent modifi- 
ers of coronary artery disease (CAD) natural history. PrescrIption rates and efficacy of 
statins have not been explicitly studied in patients (pts) with left ventricular dysfunction 
(LVD. Ejection Fraction [EFr40%). Potentially, statins could adversely effect LVD pts 
due to decreased hepatic blood flow or pharmacologic interaction (e.g with amiodarone). 
